Welcome to our dedicated page for Sanuwave Health news (Ticker: SNWV), a resource for investors and traders seeking the latest updates and insights on Sanuwave Health stock.
Sanuwave Health, Inc. (SNWV) pioneers noninvasive regenerative solutions through its proprietary PACE™ technology, advancing wound care and tissue repair innovations. This dedicated news hub provides investors and medical professionals with essential updates on the company's progress in developing FDA-cleared medical devices.
Access authoritative information about SNWV's technological advancements, including clinical trial outcomes, regulatory milestones, and strategic partnerships. Our curated collection features:
• FDA clearance announcements for new medical devices
• Clinical study results demonstrating treatment efficacy
• Financial performance updates and corporate developments
• Technology licensing agreements and partnership news
Bookmark this page for reliable updates on Sanuwave Health's progress in revolutionizing noninvasive therapies for wound management, orthopedic conditions, and aesthetic procedures. Verify all investment decisions against official SEC filings and consult medical professionals for clinical guidance.
SANUWAVE attended the 3rd Annual Leaders in Wound Healing Conference on April 18-19, 2023, in New Orleans, LA, where industry leaders discussed innovative technologies in wound care. Kevin Richardson II, CEO, emphasized their commitment to regenerative medicine and the significance of participating in such notable events. Dr. Jonathan Johnson presented on 'The Clinical Benefits of Using UltraMIST to treat VLU’s', showcasing SANUWAVE's advancements in non-invasive solutions for chronic wound healing. The company is dedicated to enhancing patient outcomes through its patented technologies, which are designed to accelerate healing processes and alleviate healthcare burdens.
SANUWAVE Health, Inc. (OTCQB: SNWV) announced its financial results for Q4 and full year 2022, highlighting a 32% revenue increase to $5.5 million in Q4 and a 29% annual revenue growth to $16.7 million. Gross margins improved to 78% in Q4 and 74% for the year. The operating loss decreased to $1.5 million in Q4 from $2.5 million in Q3 and $9.0 million for the year compared to $14.1 million prior. Despite ongoing supply constraints, the company anticipates a 14-20% revenue growth in Q1 2023. Recent team appointments aim to enhance operations and sales.
SANUWAVE Health, Inc. (OTCPK: SNWV) will host a live conference call on April 3, 2023, at 9:00 AM (EDT) to share a financial update and discuss recent strategic initiatives. Participants can access the call via a provided toll-free number or through the Call me™ link for instant access. A replay of the call will be available until April 17, 2023. SANUWAVE focuses on developing patented, non-invasive medical systems aimed at the repair and regeneration of skin and tissue. The press release includes forward-looking statements regarding financial results and business development, highlighting potential risks associated with regulatory approvals and competition.
SANUWAVE Health, Inc. (OTCQB: SNWV) announced that its common stock began trading on the OTCQB on January 30, 2023. The company specializes in the research, development, and commercialization of non-invasive medical systems designed to facilitate the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. SANUWAVE’s innovative energy transfer technologies are aimed at enhancing wound healing and have applications in orthopedic, aesthetic, and cardiac conditions. The press release also includes forward-looking statements regarding future business developments, cautioning investors about associated risks and uncertainties.
SANUWAVE Health, Inc. (OTCPK: SNWV) reported a 12% revenue increase to $4.2 million for Q3 2022, compared to $3.7 million in Q3 2021. Year-to-date revenue surged 28.5% to approximately $11.2 million. Gross margin improved significantly to 85% for Q3, up from 58% last year. Operating loss decreased to $1.8 million from $3.4 million in the prior year, with operating expenses down 17.6% to $13.9 million for nine months. The company achieved EBITDA positivity in October, indicating potential for sustained profitable growth.
SANUWAVE Health, Inc. (OTCPK: SNWV) announced the acceptance of three abstracts showcasing its dermaPACE system for chronic wound treatment at the 2022 Fall Symposium on Advanced Wound Care. The event will be held from October 13-16, 2022, in Las Vegas. The abstracts focus on various clinical applications, including treating complex wounds related to erythromelalgia and pyoderma gangrenosum. SANUWAVE's executives will be present at booth #619, highlighting their regenerative medicine product portfolio.
SANUWAVE Health, Inc. (OTC PINK:SNWV) has announced its participation in the Microcap Rodeo's Windy City Roundup 2022 conference, taking place on October 12-13, 2022. The company will present a live investor session on October 13 at 10:30 AM (CT), with a replay available shortly after. Investors can access the presentation through SANUWAVE's investor portal. The conference will feature over 60 microcap companies, providing insights into potential investment opportunities and trends for 2023.
SANUWAVE Health announces the appointment of Dr. Toni Rinow as Chief Financial Officer, effective immediately. Dr. Rinow brings over 20 years of experience in corporate development, focusing on growth and revenue acceleration. She has previously raised over $130 million for a NASDAQ-traded wellness company. CEO Kevin Richardson emphasized that her experience aligns strategically with SANUWAVE's goals post-financing. The company is dedicated to advancing non-invasive wound care technologies that enhance natural healing processes.
SANUWAVE Health, Inc. (OTCPK: SNWV) reported significant second-quarter results for 2022, with revenues of $3.9 million, marking a 33% increase from 2021. The company successfully placed over 50 wound care systems, doubling from the previous year, and administered over 40,000 wound treatments. Gross margin improved to 72% from 64%. Operating loss decreased to $2 million vs. $4 million in 2021. SANUWAVE became current with SEC filings and is positioned for profitable growth in wound care.
SANUWAVE Health (OTCQB: SNWV) has aided football legend Jim McMahon in recovering from complications due to a surgical infection using their ENERGY FIRST devices, dermaPACE® and UltraMIST®. Following his surgery in November 2021, McMahon faced healing delays, prompting the need for effective treatment. SANUWAVE's combination therapy, initiated on April 27, 2022, successfully addressed his wound, which was healed within three weeks. Kevin Richardson, CEO, expressed pride in their technology's impact on improving wound care.
